Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19

STATUS

Recruiting
participants needed

224
sponsor

Baqiyatallah Medical Sciences University

Send

Updated on 19 February 2024

See if I qualify

ct scan

dyspnea

covid-19

SARS

acute respiratory syndrome (sars)

Summary

This study is a multi-center randomized, controlled, and blinded clinical trial study that will be performed in four medical-educational centers. In this study, the samples will be selected from among patients with SARS-CoV-2 as easy access and based on entry criteria and will be randomly divided into two groups, including a control group and an intervention group. The study will be conducted in four medical centers. From each center, 56 definitive Corona patients will be selected, who will be randomly divided into two groups of 28, for a total of 224 patients will enter the study. In the intervention group, in addition to receiving the test spray, Patients will also receive standard treatment

Details

Condition	Covid 19
Age	18-75 years
Treatment	Placebo, standard treatment, PHR160 Spray
Clinical Study Identifier	NCT04463420
Sponsor	Baqiyatallah Medical Sciences University
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Patients with COVID-19 who are hospitalized
	Conscious consent to participate in the study
	Patients 18 to 75 years of age with COVID-19 who have been diagnosed with PCR
	Strong clinical suspicion of covid 19 with positive findings in CT Scan
	Shortness of breath
Exclusion Criteria
	Patients with HIV
	Patients with cancer undergoing chemotherapy
	Patients receiving Immune Mediators
	Patients need hospitalization in the intensive care unit
	Patients with uncontrolled heart, kidney or liver failure
	Pregnant or lactating women
	Intolerance to the drugs used in this study (symptoms such as diarrhea, nausea, vomiting and respiratory problems)

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

acute respiratory syndrome (sars)

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19